Number,

Medicine, 

Longevity.

Demiurge is the first and only company worldwide that has achieved an 18-month-long public track record of 85.8% (115/134) accuracy in our prospective predictions of phase 2 and phase 3 clinical trial results.  

    Thanks for submitting!    

Sign up now to receive our performance update!

Demiurge has achieved an 18-month-long public track record of 85.8% (115/134) accuracy in our prospective predictions of phase 2 and phase 3 clinical trial results. 

85.8%

PREDICTION ACCURACY RATE

as of 01 August 2021 
for all therapeutic areas excluding genetic disorders and hematological disorders. 

Demiurge Prediction Accuary Bar_edited.jpg

89.5%

PREDICTION ACCURACY RATE

Even for new diseases like COVID-19 without any preexisting clinical data, Demiurge published a detailed COVID-19 disease model in March 2020 (Lovetrue, 2020 here).

Demiurge has achieved an 18-month-long public track record 89.5% (34/38) accuracy in prospective predictions of phase 2 and phase 3 COVID-19 clinical trial results in 2020/2021.

as of 01 August 2021

Demiurge Prediction Accuary Bar_edited.jpg

+40.8%

Demiurge's prediction accuracy has beaten the weighted benchmark by a wide margin of +40.8%.   

as of 01 August 2021

Demiurge
Weighted
Benchmark
45%
85.8%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Prediction Accuracy

INDICATIONS

131

26

THERAPEUTIC ARES

Demiurge has made 280+ prospective predictions in public covering 131 indications in 26 therapeutic areas. 

as of 01 August 2021

3_edited.png
logo front page.png